

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Dated: February 12, 2004		ATTY DOCKET NO. <b>1702.4015LO</b>	APPLICATION NO. <b>Div. of 09/674,973</b>
APPLICANT <b>GUSTAV GAUDERNACK, ET AL.</b>		FILING DATE <b>February 12, 2004</b>	
GROUP <b>Unassign d</b>			

  

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

  

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT	
MB	WO 99/10382	3/1999	WIPO			Yes	
MB	WO 97/12992	4/1997	WIPO			Y s	
MB	WO 96/18409	6/1996	WIPO			Yes	
MB	WO 95/32731	12/1995	WIPO			Y s	
MB	WO 92/14756	9/1992	WIPO			Y s	

  

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	
MB	Rampino et al. (1997), Science 275:967-969, "Somatic Frameshift Mutations in the BAX Gen in Colon Cancers of the Microsatellite Mutator Pheotype".
MB	Yamamoto et al. (1998, March), Cancer Research 58:997-1003, "Somatic Frameshift Mutations in DNA Mismatch Repair and Proapoptosis Genes in Hereditary Nonpolyposis Colorectal Cancer".
MB	Markowitz et al. (1995), Science 268:1336-1338, "Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability".
MB	Gaudernack (1996), Immunotechnology 2:3-9, "T cell responses against mutant ras: a basis for novel cancer vaccines".
MB	Gjertsen et al. (1996), Int. Journal of Cancer 65:450-453, "Ex Vivo ras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of a Phase I/II Study".
MB	Gjertsen et al. (1996), British Journal of Cancer 74:1828-1833, "Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination".

  

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Dated: February 12, 2004			ATTY DOCKET NO. <b>1702.4015LO</b>		APPLICATION NO. <b>Div. of 09/674,973</b>		
			APPLICANT <b>GUSTAV GAUDERNACK, ET AL.</b>				
			FILING DATE <b>Fbruary 12, 2004</b>			GROUP <b>Unassigned</b>	

  

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

  

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT		
<b>MB</b>	<b>WO 99/58564</b>	<b>11/1999</b>	<b>WIPO</b>			<b>Yes</b>	

  

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	
<b>MB</b>	<b>Gjertsen et al. (1997), Int. J. Cancer 72:784-790, "Cytotoxic CD4<sup>+</sup> and CD8<sup>+</sup> T-Lymphocytes, Generated by Mutant p21-ras (12Val) Peptide Vaccination of a Patient, Recognize ... Tumour Cells Carrying This Mutation".</b>
<b>MB</b>	<b>Gjertsen et al. (1998) Vox Sanguinis 74(suppl. 2): 489-495, "Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer".</b>
<b>MB</b>	<b>Barinaga, (1992) Science, vol. 257, pp. 880-881, "Getting Some 'Backbone': How MHC Binds Peptides".</b>
<b>MB</b>	<b>Deres et al., (1989) Nature, vol. 342, pp. 561-564, "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine".</b>
<b>MB</b>	<b>Tighe et al., (1998) Immun. Today, vol. 19(2), pp. 89-97, "Gene vaccination: plasmid DNA is more than just a blueprint".</b>

  

EXAMINER <b>/Michael Borin/</b>	DATE CONSIDERED <b>04/26/2006</b>
------------------------------------	--------------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2